Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

NCT03123276 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Pembrolizumab
DRUG: Gemcitabine

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

Merck Sharp & Dohme LLC